CDKN2A and hepatocellular carcinoma: In contrast, two specific KAT6 inhibitors have been reported to induce cell cycle exit and cellular senescence mediated by the INK4A/ARF signaling pathway, thus suppressing the tumor proliferation of hepatocellular carcinoma and lymphoma in preclinical models [36].